Professional
Added to YB: 2024-10-02
Pitch date: 2024-10-01
IONS [bullish]
Ionis Pharmaceuticals, Inc.
+107.76%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Market Cap
$13.4B
Pitch Price
$38.90
Price Target
69.00 (-15%)
Dividend
N/A
EV/EBITDA
-55.53
P/E
-51.28
EV/Sales
13.67
Sector
Biotechnology
Category
growth
Show full summary:
Ionis Pharmaceuticals, Inc.: Following In-Line Quarter, We Raise Fair Value Estimate to $69 on Angelman Potential
IONS: Antisense oligonucleotide leader w/ broad pipeline. Wainua launch 2024 ($3B+ potential), olezarsen 2025-26. Partnerships (AZ, Biogen, Novartis) drive late-stage programs. Narrow moat from IP, but faces RNA/gene therapy competition. FVE $69. Profitable by 2027. High uncertainty due to pipeline risks.
Read full article (8 min)